Table 3

Response to first TNFα inhibitors, mean values±SD unless otherwise indicated

Improvement in clinical parameters	6 months		P value	18 months		P value
	Incl	Excl		Incl	Excl
VAS pain	−34±30	−29±28	0.50	−29±31	−25±32	0.60
VAS fatigue	−35±33	−24±29	0.19	−34±38	−23±32	0.21
VAS patient global	−41±38	−28±30	0.12	−38±43	−27±34	0.26
VAS physician global	−34±19	−32±19	0.59	−35±24	−30±27	0.38
HAQ	−0.8±0.7	−0.3±0.6	0.008*	−0.6±0.7	−0.3±0.6	0.051
SJC	−4.3±2.7	−2.2±2.7	0.001*	−4.4±3.4	−2.2±3.6	0.007*
TJC	−4.2±3.8	−2.8±5.1	0.16	−4.0±4.9	−3.9±4.1	0.89

*Denotes a p value of <0.05 by unpaired t-test.
DAPSA28, Disease Activity Score in Psoriatic Arthritis for 28 joints; HAQ, Health Assessment Questionnaire; SJC, swollen joint count; TJC, tender joint count; VAS, Visual Analogue Scale.